Article
No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Human psychopharmacology - 1 Jan 2004
Roberts Rebecca L, Mulder Roger T, Joyce Peter R, Luty Suzanne E, Kennedy Martin A
Abstract excerpt
The polymorphic enzyme cytochrome P450 CYP2D6 is involved in the metabolism of many antidepressants, including nortriptyline and fluoxetine. Some 7%-10% Caucasians have inactivating mutations in both alleles of the CYP2D6 gene, and are referred to as poor metabolizers (PMs). Several case reports and clinical studies suggest that CYP2D6 PMs are at a greater risk of developing adverse drug reactions (ADRs) on...
Topics
- Adolescent
- Adult
- Antidepressive Agents
- Cytochrome P-450 CYP2D6
- Depressive Disorder, Major
- Female
- Fluoxetine
- Genotype
- Humans
- Male
- Middle Aged